Promising targets in ADCs for breast cancer [Video]

Erika Hamilton, MD, from the Sarah Cannon Research Institute in Nashville, TN, discusses the evolving landscape of antibody drug conjugates (ADCs) in breast cancer treatment. Currently, ADCs such as trastuzumab emtansine, trastuzumab deruxtecan, and sacituzumab govitecan are approved for HER2-positive breast cancer. Dr Hamilton anticipates the approval of datopotamab deruxtecan, another ADC targeting TROP-2, in the near future. Additionally, she highlights the diverse range of targets being explored for ADC development, including b7-h4, claudin, and HER3. Notably, HER3-targeted ADCs do not require testing for HER2 status, offering potential benefits across various breast cancer subtypes. This discussion underscores the expanding therapeutic options in breast cancer treatment and the potential of ADCs to address unmet medical needs across multiple breast cancer types. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.